hrp0094p2-405 | Sex differentiation, gonads and gynaecology or sex endocrinology | ESPE2021

Serum high mobility group box 1 (HMGB1) levels are independently associated with glucose clamp-derived measures of insulin resistance in PCOS

Catellani Cecilia , Migazzi Matteo , Sartori Chiara , Dauriz Marco , Righi Beatrice , Cirillo Francesca , Villani Michela , Tosi Flavia , Moghetti Paolo , Street Maria Elisabeth

Polycystic Ovary Syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age, and is characterised by chronic inflammation and in most cases by insulin resistance besides ovulatory dysfunction and hyperandrogenism. HMGB1 is a small protein with cytokine activity that can activate nuclear factor kappa light chain enhancer of activated B cells (Nf-kB), and signals through the Receptor for advanced glycation end products (RAGEs) and through the T...

hrp0097p1-175 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

The IGF system shows changes in the follicular fluid of women with PCOS.

Sartori Chiara , Catellani Cecilia , Buia Veronica , Croci Stefania , Righi Beatrice , Morini Daria , Immacolata Falbo Angela , Nicoli Alessia , De Fanti Alessandro , Teresa Villani Maria , Elisabeth Street Maria

Background: Polycystic Ovary Syndrome (PCOS) is a common endocrine disorder among women of reproductive age and is characterised by chronic low-grade inflammation, ovulatory dysfunction and hyperandrogenism, and often by insulin resistance. The IGF system is involved in glucose metabolism regulation and is altered in chronic inflammation where both IGF-I and –II can be reduced. We previously described increased HMGB1 content in follicular fluid (FF) in P...

hrp0089p3-p205 | GH & IGFs P3 | ESPE2018

Small for Gestational Age (SGA) Patients in Real Life French Clinical Practice: What is the Difference Between Good and Poor Responders to GH Treatment

Nicolino Marc , Coutant Regis , Leheup Bruno , Salles Jean-Pierre , Hacques Evguenia , Villette Beatice

Objective: Age and height at treatment start, target height, GH dose, and first year treatment response are among known criteria of GH deficiency (GHD) good responders (final adult height [FAH] >−2 standard deviation score [S.D.S.]) to GH treatment (GHT). The authors investigated whether the same criteria are applicable to SGA patients based on real-life ongoing French registry data.Methods: 291 SGA children treated with Norditro...

hrp0092p2-232 | Pituitary, Neuroendocrinology and Puberty | ESPE2019

Childhood Craniopharyngioma: Clinical Picture at Diagnosis in an Italian Multicentre Study

Menardi Rachele , Driul Daniela , Franco Francesca , Baronio Federico , Pozzobon Gabriella , Gallo Dario , Grossi Armando , Fintini Danilo , Parpagnoli Maria , Nardini Beatrice , Matarazzo Patrizia , Ibba Anastasia , Bruzzi Patrizia , Wasniewska Malgorzata , Salerno Mariacarolina , Fantini Jacopo , Zucchini Stefano

Diagnosis of craniopharyngiomas in childhood is often delayed due to nonspecific symptoms. In Italy all children are followed-up by paediatricians of the NHS and paediatric endocrinologists are present throughout the country. This would theoretically lead to an early diagnosis. We aimed to examine the clinical picture at diagnosis and duration of history before diagnosis in 117 patients (pts) followed-up at Endocrinology Centres belonging to the I.S.P.E.D..<p class="abstex...

hrp0097fc8.3 | Fat, metabolism and obesity 2 | ESPE2023

Impact of growth hormone therapy on body mass index in childhood-onset craniopharyngioma: a multicenter Italian study in 117 patients.

Ciacchini Benedetta , Zucchini Stefano , Pozzobon Gabriella , Pedicelli Stefania , Parpagnoli Maria , Driul Daniela , Matarazzo Patrizia , Baronio Federico , Panciroli Marta , Partenope Cristina , Nardini Beatrice , Ubertini Graziamaria , Menardi Rachele , Guzzetti Chiara , Iughetti Lorenzo , Aversa Tommaso , Di Mase Raffaella , Cassio Alessandra , Di Iorgi Natascia

Background: patients with childhood-onset craniopharyngioma (CO-CP) present long-term outcomes, including growth hormone (GH) deficiency and obesity. Currently, data on the effects of GH therapy (GHT) on the body mass index (BMI) in CP are inconclusive. Aims of the study were to evaluate BMI over time and its determinants in a large cohort of CO-CP patients treated with GH therapy (GHT).Methods: a multicenter retrospecti...

hrp0097rfc3.4 | Fat, metabolism and obesity 1 | ESPE2023

Effect of maternal diet and breastfeeding on growth and distribution of adiposity from birth up to 12 months: data from the European LIFE-MILCH project

Righi Beatrice , Alberghi Francesca , Fontana Marta , Pelosi Annalisa , Davolio Emanuela , Rotteglia Cecilia , Catellani Cecilia , Sartori Chiara , Shulhai Anna-Mariia , Buia Veronica , Maria Papini Anna , Fanos Vassilios , Palanza Paola , E Street Maria

The ongoing European LIFE-MILCH project(www.lifemilch.eu), focuses on detecting Endocrine Disrupting Chemicals in mothers, in breast and formula milk and in urine of mothers and infants up to 12 months of age studying relationships with neurodevelopment, growth, distribution of adiposity, pubertal stages to establish a risk assessment model to prepare safety guidelines. In this study we have evaluated the effects of maternal diet during and after pregnancy, and of duration of ...

hrp0097p1-371 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Effect of maternal diet on pubertal stages and ano-genital distance from birth up to 12 months: data from the European LIFE-MILCH project

Alberghi Francesca , Fontana Marta , Righi Beatrice , Shulhai Anna-Mariia , Davolio Emanuela , Rotteglia Cecilia , Pelosi Annalisa , Catellani Cecilia , Sartori Chiara , Buia Veronica , Maria Papini Anna , Fanos Vassilios , Palanza Paola , E. Street Maria

The ongoing European LIFE-MILCH project (www.lifemilch.eu), focuses on detecting Endocrine Disrupting Chemicals in mothers, in breast and formula milk and in urine of mothers and infants up to 12 months of age studying relationships with neurodevelopment, growth, distribution of adiposity, pubertal stages, and ano-genital distance (AGD) to establish a risk assessment model to prepare safety guidelines. In this study we evaluated the effects of maternal diet during and after pr...

hrp0084p3-1002 | Gonads | ESPE2015

Leydig-Cell Tumour, a Rare Cause of LH-Independent Sexual Precocity in Boys

Gerard Maxime , Thomas-Teinturier Cecile , Bouvattier Claire , Mantel Anne , De Lambert Guenolee , Beaudoin Sylvie , Mussini Charlotte , Pierre Bougneres

Background: Leydig-cell tumours in children are rare, comprising only 4 to 9% of all primary testis tumours in prepubertal males. These boys present with isosexual precocious pseudopuberty characterized by increased testosterone and low gonadotropin levels. We describe two cases and will discuss differential diagnosis and pathogenesis.Case 1: C. was first referred at 8 years old for pubertal development with accelerated growth since 4 years of age. His v...

hrp0089p1-p001 | Adrenals and HPA Axis P1 | ESPE2018

Evaluation of Long Term Metabolic Effects After Prenatal Dexamethasone Treatment in the Context of CAH – the Swedish Cohort

Wallensteen Lena , Karlsson Leif , Messina Valeria , Nordenstrom Anna , Lajic Svetlana

Background: Prenatal dexamethasone (DEX) treatment is in many countries offered to the pregnant woman, at risk of having a child with classic congenital adrenal hyperplasia (CAH), to reduce virilization in an affected female fetus. The treatment is effective in reducing virilization but may give long lasting effects on somatic and cognitive health. Here, we explore the potential effect on metabolism in children and adults not having CAH and exposed to DEX during the first trim...

hrp0089p1-p003 | Adrenals and HPA Axis P1 | ESPE2018

Cognition in Children with Congenital Adrenal Hyperplasia

Messina Valeria , Karlsson Leif , Hirvikoski Tatja , Nordenstrom Anna , Lajic Svetlana

Background: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive disorders, affecting around 1/10 000 newborns worldwide. Postnatally, patients with classic CAH are treated with life-long glucocorticoid (GC) replacement therapy, such as hydrocortisone or prednisolone, and in the more severe cases also with mineralocorticoids. A negative impact of GCs on human cognition such as memory deficits have been reported bot...